The cost effectiveness of implantable cardioverter defibrillators: A systematic review of economic evaluations

Applied Health Economics and Health Policy

Volumn 12, Issue 1, 2014, Pages 41-49

  Gialama, Fotini ^a   Prezerakos, Panagiotis ^b   Maniadakis, Nikos ^a  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b UNIVERSITY OF PELOPONNESE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE POLICY; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SYSTEMATIC REVIEW;

ANTI-ARRHYTHMIA AGENTS; COST-BENEFIT ANALYSIS; DATABASES, BIBLIOGRAPHIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART DISEASES; HUMANS; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; SECONDARY PREVENTION;

EID: 84893549399     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0069-2     Document Type: Review

References (66)

1. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98(21):2334-51.
2. Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation. 2004;109:2685-91.
3. Myerburg RJ et al. Frequency of sudden cardiac death and profiles of risk. Am J Cardiol. 1997;80(suppl. 5B):10F-9F.
4. Weisfeldt ML, Zieman SJ. Advances in the prevention and treatment of cardiovascular disease. Health Aff (Millwood). 2007;26(1):25-37.
5. Campbell TJ, Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol. 1998;46(4):307-19.
6. Reiffel J, Dizon J. The implantable cardioverter-defibrillator: patient perspective. Circulation. 2002;105(9):1022-4.
7. Epstein A, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. J Am Coll Cardiol. 2008;51(21).
8. Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7).
9. Ofman JJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manage Care Pharm. 2003;9(1):53-61.
10. Kupersmith J, et al. Evaluating and improving the cost-effectiveness of the implantable cardioverter-defibrillator. Am Heart J. 1995;130(3 Pt 1):507-15.
11. Kuppermann M, et al. An analysis of the cost effectiveness of the implantable defibrillator. Circulation. 1990;81(1):91-100.
12. Larsen G, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation. 2002;105(17):2049-57.
13. O'Brien BJ, Buxton MJ, Rushby JA. Cost effectiveness of the implantable cardioverter defibrillator: a preliminary analysis. Br Heart J. 1992;68(2):241-5.
14. O'Brien BJ, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2001;103(10):1416-21.
15. Sheldon R, et al. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. Circulation. 2001;104(14):1622-6.
16. Weiss JP, et al. Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among medicare beneficiaries. Am J Med. 2002;112(7):519-27.
17. Wever EF, et al. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors. A randomized study. Circulation. 1996;93(3):489-96.
18. Larsen GC, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol. 1992;19(6):1323-34.
19. Owens DK, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med. 1997;126(1):1-12.
20. Owens DK, et al. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J. 2002;144(3):440-8.
21. Cowie MR, et al. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace. 2009;11(6):716-26.
22. Gandjour A, et al. Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II). Value Health. 2011;14(6):812-7.
23. Mark DB, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2006;114(2):135-42.
24. Neyt M, et al. Cost effectiveness of implantable cardioverter- defibrillators for primary prevention in a Belgian context. Appl Health Econ Health Policy. 2008;6(1):67-80.
25. Ribeiro RA, et al. Cost-effectiveness of implantable cardioverter- defibrillators in Brazil: primary prevention analysis in the public sector. Value Health. 2010;13(2):160-8.
26. Ribeiro RA, et al. Cost-effectiveness of implantable cardioverter defibrillators in Brazil in the public and private sectors. Arq Bras Cardiol. 2010;95(5):577-86.
27. Sanders GD, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med. 2001;135(10):870-83.
28. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353(14):1471-80.
29. Sanders GD, et al. Cost-effectiveness of implantable cardioverter defibrillators in patients > or = 65 years of age. Am Heart J. 2010;160(1):122-31.
30. Sanders GD, et al. Special report: cost-effectiveness of implantable cardioverter-defibrillators in a MADIT-II population. Technol Eval Cent Assess Program Exec Summ. 2004;19(3):1-2.
31. Wang K, et al. Cost-effectiveness of implantable cardioverter- defibrillators in Brugada syndrome treatment. J Med Syst. 2008;32(1):51-7.
32. You JJ, et al. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Am Heart J. 2007;154(5):899-907.
33. Al-Khatib SM, et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med. 2005;142(8):593-600.
34. Groeneveld PW, et al. Outcomes and costs of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death among the elderly. Heart Rhythm. 2008;5(5):646-53.
35. Mushlin AI, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation. 1998;97(21):2129-35.
36. Zwanziger J, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47(11):2310-8.
37. Chen L, Hay JW. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther. 2004;18(2):161-70.
38. Feingold B, et al. Cost-effectiveness of implantable cardioverter- defibrillators in children with dilated cardiomyopathy. J Card Fail. 2010;16(9):734-41.
39. Goldenberg I, et al. Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvasive Electrocardiol. 2005;10:67-83.
40. Smith T, et al. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. Eur Heart J. 2013;34(3):211-9.
41. Caro JJ, et al. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone. Value Health. 2007;10(1):13-22.
42. Deniz HB, et al. Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada. Curr Med Res Opin. 2009;25(3):617-26.
43. Goldberger Z, et al. Cost advantage of dual-chamber versus single-chamber cardioverter-defibrillator implantation. J Am Coll Cardiol. 2005;46(5):850-7.
44. Valenti R, et al. Impact of the implantable cardioverter-defibrillator on rehospitalizations. Eur Heart J. 1996;17(10):1565-71.
45. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol. 2008;52(14):1111-21.
46. Irvine J, et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J. 2002;144(2):282-9.
47. Namerow PB, et al. Quality-of-life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: findings from the CABG Patch Trial. Pacing Clin Electrophysiol. 1999;22(9):1305-13.
48. Boriani G, et al. Implantable cardioverter defibrillators: from evidence of trials to clinical practice. Eur Heart J Suppl. 2007;9:166-73.
49. Moss AJ. Implantable cardioverter defibrillator therapy: the sickest patients benefit the most. Circulation. 2000;101:1638-40.
50. Lee DS, et al. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol. 2007;49(25):2408-15.
51. Chan PS, et al. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention. Circ Cardiovasc Qual Outcomes. 2009;2(1):16-24.
52. Mezu U, et al. Effectiveness of implantable defibrillators in octogenarians and nonagenarians for primary prevention of sudden cardiac death. Am J Cardiol. 2011;108(5):718-22.
53. Hartling L, et al. Challenges in systematic reviews of therapeutic devices and procedures. Ann Intern Med. 2005;142(12 Pt 2):1100-11.
54. Pignone M, et al. Challenges in systematic reviews of economic analyses. Ann Intern Med. 2005;142(12 Pt 2):1073-9.
55. Stanton MS, Bell GK. Economic outcomes of implantable cardioverter-defibrillators. Circulation. 2000;101(9):1067-74.
56. Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ. 2010;19(3):350-64.
57. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: Part II. Circulation. 2002;106(5):626-30.
58. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: part I. Circulation. 2002;106(4):516-20.
59. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal; 2008.
60. Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003;1(1):8.
61. World Health Organization. Choosing interventions that are cost-effective (WHO-CHOICE); 2011. http://www.who.int/choice/costs/CER-levels/en/index.html.
62. Adang E, et al. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions. Health Policy. 2005;74(2):146-56.
63. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med. 1998;13(10):716-7.
64. Boriani G, et al. Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs. Eur J Heart Fail. 2003;5(4):419-25.
65. Boriani G, et al. Cost-effectiveness of implantable cardioverter- defibrillators. Eur Heart J. 2001;22(12):990-6.
66. Hlatky MA, Bigger T. Cost-effectiveness of the implantable cardioverter defibrillator? Lancet. 2001;357(9271):1817-8.